Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokineti... (ttention and poor memory. Current antips...)

HOME >> MEDICINE >> TECHNOLOGY

Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings

Date:2/19/2013

ttention and poor memory. Current antipsychotics are effective primarily on reducing positive symptoms but are largely ineffective at reducing negative and cognitive symptoms. The medical need in this disease area is enormous.

About PDE1 Inhibitors

These compounds are unique, orally available, investigational drugs being developed for the treatment of cognitive impairments accompanying schizophrenia and other neurological and neuropsychiatric disorders, including Alzheimer's disease, Attention Deficit Hyperactivity Disorder and Parkinson's disease. These compounds may also have the potential to improve motor dysfunction associated with these disorders. These compounds are very selective for the PDE1 subfamily relative to other PDE subfamilies. They have no known significant off target activities at other enzymes, receptors or ion channels.

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company was formed in 2002 to exploit intracellular signaling pathways of the brain in its efforts to develop novel CNS therapeutics. The Company's initial efforts were built on the insights generated from the Nobel Prize winning science of Dr. Paul Greengard at The Rockefeller University, the scientific founder of ITI. Using novel technologies developed at ITI, the Company has developed a pipeline of drugs that have the potential to treat a wide range of diseases associated with the CNS. Additional information about ITI is available through its corporate website, www.intracellulartherapies.com.

CONTACT:
Allen A. Fienberg , Ph.D., Vice President, Business Development, Intra-Cellular Therapies, Inc., +1-212-923-3344; or Lisa Burns
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
2. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
3. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
4. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
5. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
6. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
7. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
8. Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
9. Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for Effective, Affordable Therapies
10. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
11. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise

Post Your Comments:

(Date:5/24/2013)... 24, 2013 China Biologic Products, Inc. (Nasdaq: ... integrated plasma-based biopharmaceutical company in China ... from a public announcement issued by Shanghai RAAS Blood ... on Shenzhen Stock Exchange, that on May 21, 2013, ... Chan"), one of the shareholders of the Company, and ...

(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013 Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel. Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...

(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer"). On 20 May ...

[0] China Biologic Comments on the Proposed Shanghai RAAS Transaction [0] Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

... , CAMBRIDGE, Mass., Nov. 19 Ligon Discovery, ... find drugs against high-value targets, today announced that it ... Ventures. The company will use the capital to complete ... high-value disease protein targets. With this investment, incTANK Ventures ...

... , Part of ... Md., Nov. 19 The U.S. Food and Drug ... the International Internet Week of Action (IIWA), intended to ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s Office ...

Cached Medicine Technology:Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2 Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3 UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2

Cambridge-based Ligon Discovery Raises $1M in Seed Funding UPDATE: FDA Issues 22 Warning Letters to Web site Operators

(Date:5/24/2013)... The British Menopause Society and Women,s Health Concern have ... to provide clarity around the role of HRT, the ... the society,s flagship title, Menopause International , published ... HRT has changed from being branded the "elixir of ... be used in certain circumstances. Since the publication of ...

(Date:5/24/2013)... Today marks the launch of Destination ... , The redesigned and enhanced Itinerary Builder will ... on their computer or mobile device that they can ... allows users to fill in their date of arrival ... their choice of vacation packages, accommodations, restaurants, and things ...

(Date:5/24/2013)... Wixom, MI (PRWEB) May 24, 2013 ... recent Cute Baby Photo Contest. Lindsey Willis of Olathe, ... Cuties-brand diapers from DiaperBuys. Second prize was a ... Heather Tacher, North Las Vegas, Nev.; and third prize, ... Texas. , The contest was run through the company’s ...

(Date:5/24/2013)... 2013 Wednesday, 15th May 2013 | 10am ... to access webinar playback: http://bit.ly/10Rt0ZH , Ongoing regulatory ... markets. Across the globe and particularly in Europe, a number ... M&A activity . For dealmakers, understanding how the likes of ... Tax’ affects your corner of the market will give you ...

(Date:5/24/2013)... San Diego, CA (PRWEB) May 24, 2013 ... informing consumers today of the latest update involving ... Zithromax and Zmax SR (azithromycin) can allegedly ... Canadian Broadcasting Company reported on May 17, 2013* ... and Drug Administration in warning that Zithromax can ...

Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2 Health News:DiaperBuys.com Announces Photo Contest Winners 2 Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2 Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3 Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2 Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3 Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4

[0] Hormone replacement therapy -- clarity at last![0] Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder [0] DiaperBuys.com Announces Photo Contest Winners [0] Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 [0] 2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning

... implants created using stem cells can only be constructed ... before the almost inevitable need for total joint replacement. ... investigating the possibilities of a biologically-engineered synthetic liquid polymer ... offering a one stop, permanent solution. ...

... caregivers to hospital patients, coordinating and providing direct care and delivering ... ensure that each of its patient-care units has an adequate number ... number of hours nurses work known as the "target level" ... flow of patients and their need for care. Too many nurses ...

... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... target levels in a large hospital, more patients died, a ... an era of nursing shortages and cost-cutting, in that the ... authors of the research, appearing in the March 17 issue ...

... By Amanda Gardner HealthDay Reporter , ... the tsunami that devastated the nuclear complex in Japan ... that any radiation from the unfolding disaster across the ... say. The chances of any radioactive plume reaching ...

... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... treatment to show a benefit for women with a rare ... even a treatment. The drug, sirolimus (Rapamycin), improved both ... lymphangioleiomyomatosis, or LAM, according to a study published online March ...

... recent study from North Carolina State University shows that while ... has grown, fund support for park operations has been significantly ... growth endangers the more than $20 billion in economic impact ... the reduction in general-fund support for operations puts stress on ...

Cached Medicine News:Health News:Liquid biomaterials take stem cell therapy to new level 2 Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2 Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3 Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2 Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2 Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3 Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4 Health News:Transplant Drug May Fight Rare Lung Disorder 2 Health News:Transplant Drug May Fight Rare Lung Disorder 3 Health News:Study shows attendance at state parks grows, even as funding decreases 2

Liquid biomaterials take stem cell therapy to new level Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds When Nurse Staffing Drops, Mortality Rates Rise: Study Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say Transplant Drug May Fight Rare Lung Disorder Study shows attendance at state parks grows, even as funding decreases

... TME 227 T is a ... temporary cardiac pacing and monitoring ... The TME 227 T features ... myocardium, which allows safe and ...

For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....

Medicine Products:

TME 227 TC TME 63 TC TME 61 S TME 65 S